Conference call regarding the acquisition of Igenomix

Invitation to attend Vitrolife’s conference call regarding the acquisition of Igenomix. The presentation will be held in English.

Time: Friday 9 July, 2021 at 10.00 a.m. CET.

Registration can preferably be done 10-15 minutes before the conference start time on:

Sweden dial in number: +46 (0)8 566 184 67
International dial in number: +44 (0) 2071 928338
Conference name: Vitrolife, conference ID: 5694413

Vitrolife participants:
Thomas Axelsson, CEO
Mikael Engblom, CFO
 
Before the conference call, presentation material will be available at the company web page, https://www.vitrolife.com/investors/Presentations/

A recorded version of the telephone conference will be available for seven days on number
+44 (0) 333 300 9785 (International), access code 5694413.

Gothenburg, 8 July 2021
VITROLIFE AB (publ)

For further information, please contact:
Mikael Engblom, CFO, +46 (0) 31 721 80 14

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

_________________________________________________________________________________________________________________

Vitrolife is an international medical device Group. Vitrolife develops, produces and markets medical devices for assisted reproduction.

Vitrolife has approximately 400 employees and the company's products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/